Abstract |
The effect of KW-2228, a derivative of recombinant human granulocyte colony stimulating factor, on neutropenia in children was studied in 23 cases of aplastic anemia, 13 cases of chronic benign neutropenia, 6 cases of congenital neutropenia (Kostmann type), 2 cases of cyclic neutropenia, 2 cases associated with glycogenosis type Ib and 1 cases associated with immune deficiency. KW-2228 was administered at 1-8 micrograms/kg subcutaneously and at 2-16 micrograms/kg intravenously. As a principle, the administration was started at low doses and continued for 7-28 days increasing the doses in the cases who didn't respond to the treatment well. The response rate of all the cases by the physicians in charge was 81. 8% (36/44). The mean absolute neutrophil count was increased from 304 to 1,300/microliters in aplastic anemia, from 204 to 3,027/microliters in chronic benign type, from 125 to 2,193/microliters in Kostmann type, and from 360 to 2,007 microliters in others. KW-2228 did not induce any noteworthy serious side effects. These results indicated that KW-2228 is a useful drug to treat neutropenia in children.
|
Authors | M Sakurai, M Ito, Y Hanawa, I Tsukimoto, S Imashuku, K Ueda, H Nishihira, T Fujimoto, Y Ohashi |
Journal | [Rinsho ketsueki] The Japanese journal of clinical hematology
(Rinsho Ketsueki)
Vol. 34
Issue 2
Pg. 111-8
(Feb 1993)
ISSN: 0485-1439 [Print] Japan |
PMID | 7684091
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Granulocyte Colony-Stimulating Factor
- nartograstim
|
Topics |
- Adolescent
- Age Factors
- Anemia, Aplastic
(blood, drug therapy)
- Child
- Child, Preschool
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage, therapeutic use)
- Humans
- Infant
- Infant, Newborn
- Injections, Intravenous
- Injections, Subcutaneous
- Male
- Neutropenia
(classification, drug therapy)
|